The controversy over Mylan Pharmaceuticals Inc.’s price increases for EpiPen (epinephrine) puts a spotlight on the growing trend in the private insurance market toward requiring members to meet an annual deductible before prescription drug coverage begins.
Mylan executives pointed to the trend in two recent statements responding to intense criticism from politicians and the public over...







